Intended for healthcare professionals


NICE reconsiders esketamine for depression

BMJ 2020; 370 doi: (Published 04 September 2020) Cite this as: BMJ 2020;370:m3479
  1. Elisabeth Mahase
  1. The BMJ

The National Institute for Health and Care Excellence (NICE) has launched a second consultation on the use of esketamine for treatment resistant depression, after feedback showed that it could benefit some patients.

Guidance published in January 2020 did not recommend esketamine for treatment resistant depression and said that the drug should not be made available on the NHS because of uncertainties over its clinical efficacy and cost effectiveness.1

However, NICE has now said that a second consultation is required, as “comments from the first consultation suggested esketamine may be used in …

View Full Text

Log in

Log in through your institution


* For online subscription